The death ligand Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand) eradicates many tumor types while sparing most normal tissues. However, some tumors are resistant to TRAIL. We therefore determined if TRAIL cooperates with cytosine deaminase/5-fluorocytosine (CD/5-FC) gene therapy and investigated the mechanisms involved. Transfection of human LAN-5 neuroblastoma cells with CD rendered the cells (LAN-5-CD) sensitive to 5-FC-induced, caspase-dependent apoptosis. Mediated by caspase-3, CD/5-FC and TRAIL cooperated to induce apoptosis in these TRAIL-resistant cells and to cleave X-linked inhibitor of apoptosis protein (XIAP). In established LAN-5-CD tumors growing subcutaneously in mice, intratumorally applied TRAIL did not decrease tumor growth and systemically administered 5-FC only attenuated tumor growth. In contrast, 5-FC together with TRAIL dramatically decreased tumor growth and eradicated a tumor. Assuming sufficient gene transfer of CD in situ, CD/5-FC with TRAIL may be useful for the therapy of tumors resistant to TRAIL.
Introduction
The death ligand Apo2L/TRAIL (Apo2 ligand/tumor necrosis factor-related apoptosis-inducing ligand) is a promising cancer drug since it kills many tumor cell types while, when given in a non-polyhistidine-tagged form, sparing most normal tissues. [1] [2] [3] [4] [5] TRAIL is known to induce apoptosis by binding to its agonistic receptors TRAIL-R1 and TRAIL-R2 (KILLER, TRICK2). 6 Upon receptor aggregation a death-inducing signaling complex (DISC) is formed, consisting of TRAIL, TRAIL-R1 and/ or TRAIL-R2, fas-associated protein with death domain (FADD) and caspase-8 and -10. [6] [7] [8] Following caspase cleavage at the DISC the caspase cascade is activated. Caspase-8 activation at the DISC can be inhibited by FLICE-inhibitory protein (FLIP). 9 The physiological role of the long form of FLIP (FLIP L ) has been controversial, as some studies have shown a proapoptotic function of FLIP L while others have demonstrated an antiapoptotic function (reviewed in Krueger et al. 10 ). Selective knockdown of FLIP L has recently been shown to sensitize diverse tumor cell lines to TRAIL. 11, 12 The antiapoptotic function of FLIP L is further underscored by numerous studies with diverse cancer cell lines showing that the expression level of FLIP L determines sensitivity or resistance to TRAIL (reviewed in Roth and Reed 13 ). While in some cell types mitochondrial apoptogenic function is dispensable for TRAIL-induced apoptosis, 14 mitochondria appear to contribute to TRAIL-mediated apoptosis in other cell types. 15 X-linked inhibitor of apoptosis protein (XIAP) is a pivotal inhibitor of apoptosis, since it inhibits several crucial pathways to apoptosis. Thus, it blocks mitochondria-mediated apoptosis by inhibiting caspase-9 via its baculovirus inhibitor of apoptosis repeat (BIR) 3 domain and receptor-mediated apoptosis by blocking caspase-3 using its BIR 2 domain, while in turn being cleaved by these activated caspases into fragments with less inhibitory potency. 16 In addition, its RING (really interesting new gene) domain has E3 ubiquitin ligase activity, that targets active caspase-3 and caspase-9 for degradation by the proteasome. 17, 18 TRAIL induces Bid-mediated, Baxdependent and Bcl-2 inhibitable release of mitochondrial Smac/DIABLO (second mitochondria-derived activator of caspase/direct inhibitor of apoptosis-binding protein with low pI), which abrogates the inhibitory effect of XIAP on caspases by blocking the BIR 1 and 2 domains. [19] [20] [21] Not all tumors are sensitive to TRAIL due to diverse resistance mechanisms that include the expression of XIAP [22] [23] [24] [25] [26] and of FLIP. 27, 28 However, many TRAIL-resistant tumors can be sensitized to TRAIL by a variety of therapeutic moieties (reviewed in Shankar and Srivastava 29 ), such as cancer drugs, including 5-fluorouracil (5-FU). [30] [31] [32] [33] Concerted caspase activation was shown to contribute to this cooperative effect. 31 5-FU enhanced the expression of DR4 and DR5 34 and of p53 and Bax, 32 with Bax acting as a mediator of synergy between 5-FU and TRAIL. 35 5-FU also sensitizes to TRAIL by decreasing FLIP L 36 or by increasing the ratio of caspase-8 to FLIP at the DISC. 12 However, systemic administration of chemotherapeutic drugs such as 5-FU is limited by resistance of tumors and by dose-limiting side effects. We thus reasoned that gene-directed enzyme prodrug therapy using cytosine deaminase (CD) to produce very high 5-FU levels within the tumor cells without causing systemic toxicity would be advantageous. Cytosine deaminase/5-fluorocytosine (CD/5-FC) exerts a strong bystander effect by efflux of 5-FU from transfected cells and uptake from the interstitial space by nontransfected cells. 37 While CD/5-FC is known to cause apoptosis, 38 the molecular mechanisms of CD/5-FCinduced apoptosis are incompletely understood. 39 Given emerging evidence that suicide genes enhance the efficacy of TRAIL, we determined if TRAIL cooperates with CD/5-FC and investigated the mechanisms involved. We show in this paper that TRAIL and CD/5-FC collaborate in vitro and in vivo to kill TRAIL-resistant human neuroblastoma cells. Cooperation depended on activation of caspase-3 and involved caspase-3-dependent cleavage of XIAP. Combining TRAIL with CD/5-FC gene therapy may constitute a promising approach to the therapy of TRAIL-resistant tumors.
Materials and methods

Vectors
For transfection of LAN-5 cells, Escherichia coli cytosine deaminase cDNA was cloned into the mammalian expression vector pUHD-10 using standard DNA recombination techniques (pUHD-10-1-CD). 40 The vector pSV containing the neomycin-resistant gene cDNA (pSVneo) was used for selection.
For transduction of NXS2 cells E. coli cytosine deaminase cDNA was cloned into the retroviral vector pBabe (pBabe-CD).
Cells
Human LAN-5 neuroblastoma cells (a gift from M. Schwab, DKFZ, Heidelberg, Germany) were cotransfected with pUHD-10-1-CD or empty pUHD-10-1 vector and pSVneo using Lipofectin (Life Technologies Inc., Eggenstein, Germany). Stable transfectants were selected using 500 mg/ml G418 (Life Technologies). Several clones were randomly picked and their sensitivity to 5-FC determined by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assay. Since the sensitivity of the clones to 5-FC was similar (data not shown), one clone was chosen for further experiments. This clone was not selected for high copy number of CD and therefore did not differ from the bulk culture it was derived from. LAN-5-mock cells represent LAN-5 cells stably transfected with empty pUHD-10-1 and pSVneo. Cells were cultured in collagen I-coated plastic ware (BectonDickinson, Heidelberg, Germany) in RPMI 1640 medium (Life Technologies) supplemented with 10% heat-inactivated fetal calf serum (FCS) (Biochrom, Berlin, Germany), 10 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.3 (Biochrom), 100 U/ml penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technologies), 2 mM L-glutamine (Biochrom) and 500 mg/ml G418 (Life Technologies).
The packaging cell line EcoPack-293 (BD-Clontech, Heidelberg, Germany) was transfected with pBabe-CD or empty pBabe vector using the liposomal transfection reagent GenePORTER (Gene Therapy Systems Inc., Erlangen, Germany) according to the manufacturer's instructions. Viral supernatants from transiently transfected EcoPack-293 cells diluted 1:5 with serum-free Dulbecco's modified Eagle's medium (DMEM; Life Technologies) were used to transduce NXS2 murine neuroblastoma cells (a gift from R. Reisfeld at the Scripps Institute, La Jolla, CA, USA) according to the manufacturer's manual. Stable bulk cultures (NXS2-CD and NXS2-mock) were generated using puromycin at a concentration of 1.3 mg/ml for 14 days. Cells were maintained in supplemented DMEM with 10% heatinactivated FCS (Biochrom), 10 mM HEPES, pH 7.3 (Biochrom), 100 U/ml penicillin (Life Technologies), 100 mg/ml streptomycin (Life Technologies) and 2 mM L-glutamine (Biochrom) on collagen I-coated plastic ware.
All cells were maintained at 37.01C and 5% CO 2 in a humidified atmosphere.
Drugs 5-Fluorocytosine was from Sigma (Deisenhofen, Germany). Human recombinant (rh) Apo2L/TRAIL was from Peprotech-TEBU (Frankfurt, Germany).
MTT assay
To determine the number of metabolically active cells as a measure of survival the MTT assay was employed. The tetrazolium dye procedure was performed as described 41 with some modifications. Cells were incubated in RPMI 1640 without phenol red and without serum with 1 mg/ml MTT for 3 h at 371C. The incubation medium was removed and formazan was dissolved with isopropanol. Optical density was measured with a Bio-Tek ELX800 photometer at 550 nm with the reference wavelength set at 630 nm using wells without cells as blanks.
Apoptosis assay
Apoptosis was assessed by quantifying DNA fragmentation using FACS analysis (FACScan and CELLQuest software, Becton Dickinson, Heidelberg, Germany) counting hypodiploid (sub-G1) propidium iodide-stained nuclei as described. 42 The percentage of specific apoptosis was calculated as follows: (experimental apoptosis (%)Àspontaneous apoptosis in medium (%))/(100%À spontaneous apoptosis in medium (%)) Â 100.
Clonogenic growth assay A total of 2 Â 10 4 LAN-5 CD or LAN-5-mock cells per well were plated into 6-well plates, allowed to attach overnight and then treated with 5-FC in indicated concentrations for 3 days. Cells were then cultured without 5-FC for additional 6 days. Colonies were visualized by crystal violet staining.
Inhibition of caspases
The broad-spectrum tripeptide inhibitor of caspases benzyloxycarbonyl-Val-Ala-Asp-fluoromethylketone (Z-VAD.FMK; Bachem, Bubendorf, Switzerland) was given at a concentration of 50 mM for the initial 48 h of the experiment. This was followed by an additional dose of 50 mM thereafter to compensate for possible degradation of Z-VAD.FMK.
To inhibit caspase-3 Asp-Glu-Val-Asp.fluoromethylketone (Z-DEVD.FMK; BD Pharmingen, Heidelberg, Germany) was given in two doses of 25 mg spaced 24 h apart.
Western blot analysis Cells were lysed for 30 min at 41C in phosphate-buffered saline (PBS) with 0.5% Triton-X 100 (Serva, Heidelberg, Germany) and 1 mM phenylmethylsulfonyl fluoride (Sigma). Protein concentration was assayed using bicinchoninic acid (Pierce, Rockford, IL). A total of 40 mg protein per lane was separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and electroblotted onto nitrocellulose (Amersham Pharmacia, Braunschweig, Germany). After blocking for 1 h in PBS supplemented with 5% bovine serum albumin (Sigma) and 0.1% Tween 20 (Sigma), immunodetection of p53 (BD Pharmingen; 1:1000), p21 (BD Pharmingen; 1:5000), p16 (BD Pharmingen; 1:1000), Bax (Calbiochem, Darmstadt, Germany; 1:1000), FLIP L (a gift from P. Krammer, Heidelberg; 1:10), caspase-8 (Alexis, San Diego, CA; 1:2000), caspase-3 (BD Transduction, Heidelberg, Germany; 1:1000), XIAP (BD Pharmingen 1:1000), poly-(ADP-ribose) polymerase (PARP; BD Pharmingen 1:5000) and b-actin (Sigma; 1:5000) was performed using horseradish peroxidase-coupled goat anti-mouse IgG or goat anti-rabbit IgG (both from Santa Cruz Biotechnology, Santa Cruz, CA, USA; 1:5000) as secondary antibodies. Enhanced chemiluminescence substrate (ECL, Amersham Pharmacia) was employed for detection.
Proteasome activity
Proteasome activity was determined as described. 43 Briefly, cells were trypsinized, washed twice with PBS, resuspended in 200 ml lysis buffer (0.035 % sodium dodecyl sulfate, 5 mM 3-[(3-cholamidopropyl)dimethylammonio]-1-propane sulfonate, 0.5 mM ethylenediaminetetraacetic acid, 50 mM HEPES, pH 7.5) and incubated at 41C for 1 h. The lysate was centrifuged with 14 000 r.p.m. for 10 min and the supernatant stored at À201C. Protein concentration was assayed using bicinchoninic acid (Pierce). A total of 50 mg protein in 90 ml lysis buffer per well of a 96-well plate was incubated with 10 ml of 150 mM Suc-Leu-Leu-Val-Tyr-AMC fluorescent substrate (Bachem, Weil am Rhein, Germany) at 371C for 10 min in duplicate. The released fluorochrome was measured using a Victor fluorometer (PerkinElmer, Rodgau-Ju¨gesheim, Germany) with excitation wavelength set at 355 nm and emission wavelength set at 460 nm. Cells analyzed included controls treated with 1 mM of the proteasome inhibitor MG-132 for 48 h.
Real-time RT-PCR RNA was extracted using the RNEasy kit (Qiagen, Hilden, Germany). A total of 1 mg RNA was transcribed into first strand cDNA employing the reverse transcription-(RT)-PCR core Kit from Applied Biosystems (Foster City, CA, USA) with random hexamer primers according to the manufacturer's specification. Real-time PCR was carried out using a LightCycler instrument (Roche Diagnostics, Penzberg, Germany). Primer sequences for FLIP L were as published 44 The plateau of the PCR was reached between 23 and 27 cycles. After the final cycle melting curve analysis was performed over the range of 65-951C to confirm correct product amplification. The relative expression (R) of FLIP mRNA compared to 18S rRNA was calculated using the formula:
with E representing the RT-PCR efficiency and DCP the difference of crossing points. 45 Mouse model Female RAG2 À/À /cgc À/À mice (6-8-week old) bred in the Animal Research Center of the University of Ulm and housed in sterile isolators were used. All experiments were done in accordance with institutional and state guidelines for the care and protection of animals. A total of 5 Â 10 6 viable LAN-5-CD cells were injected subcutaneously (s.c.) in the flank and treatment was started when tumors became palpable. Mice received 500 mg/kg 5-FC in 600 ml PBS intraperitoneally (i.p.) daily for 14 days and 100 ml PBS intratumorally on days 3 and 10 (5-FC group, n ¼ 6), 20 mg rhTRAIL in 100 ml PBS intratumorally on days 3 and 10 (TRAIL group, n ¼ 6), 500 mg/kg 5-FC i.p. daily for 14 days plus 20 mg rhTRAIL intratumorally on days 3 and 10 (5-FC þ TRAIL group, n ¼ 5), and PBS i.p. daily for 14 days and intratumorally on days 3 and 10 (control group, n ¼ 7). Tumors were measured with calipers in two dimensions. Tumor volumes were calculated using the formula: 0.5 Â length Â width 2 . Animals were killed when tumors exceeded a diameter of 1.5 cm or exulcerated. TRAIL 0 ng/ml TRAIL 25 ng/ml TRAIL 50 ng/ml TRAIL 100 ng/ml TRAIL 200 ng/ml TRAIL 400 ng/ml TRAIL 800 ng/ml TRAIL 1000 ng/ml CD/5-FC sensitizes to TRAIL depending on caspase activation To determine whether CD/5-FC may sensitize to TRAIL, we investigated the effect of sequential administration of these modalities on apoptosis of LAN derivatives. Compared to the effect of each single modality, pretreatment with 5-FC followed by the addition of TRAIL markedly enhanced apoptosis of LAN-5-CD but not of LAN-mock cells (Figure 3 ). To begin investigating potential mechanisms of this sensitization, we asked whether blocking caspase activation would decrease sensitization. Indeed, the broad-spectrum caspase inhibitor Z-VAD.FMK decreased the cooperative effect 
Results
LAN-5 is resistant to TRAIL
CD/5-FC induces p53 and p21 but not BAX, TRAIL-R2 or p16
Since p53 is involved in 5-FU-induced apoptosis, 49 we asked, whether p53 plays a role in the cooperation between CD/5-FC and TRAIL. Early time points were chosen for analysis to prevent confounding effects by latestage apoptosis. P53, evident in LAN-5 derivatives before CD/5-FC, increased in response to CD/5-FC after 48 h of 5-FC concomitantly with a slight increase of p21, a target gene of p53 (Figure 4a ). These increases were not modulated by the addition of TRAIL for 2 h. Interestingly, CD/5-FC did not induce the proapoptotic p53 target genes Bax (Figure 4 ) and TRAIL-R2 (data not shown). Thus, these known mechanisms of sensitization to TRAIL are not operational in the cooperation between CD/5-FC and TRAIL in LAN-5 neuroblastoma cells.
Neither 5-FC nor TRAIL or the combination of both induced p16, a pivotal positive regulator of senescence ( Figure 4 ) and LAN-5 cells did become positive for senescence-associated b-galactosidase activity (data not shown). These data argue against a role of senescence during treatment of LAN-5 with CD/5-FC and TRAIL.
CD/5-FC and TRAIL cooperate in the cleavage of XIAP Since downregulation of XIAP may sensitize to CD/5-FC or TRAIL, we investigated the hitherto unknown effects of CD/5-FC given alone or in combination with TRAIL on XIAP (Figure 4) . Again, early time points were chosen for analysis to prevent confounding effects by late-stage apoptosis. XIAP was strongly expressed in LAN-5 derivatives. XIAP was not cleaved after 48 h of CD/5-FC. XIAP was partially cleaved during TRAIL treatment in both LAN-5-CD and LAN-5-mock as demonstrated by the small decrease of the inhibitory p57 and the appearance of the noninhibitory 50 p29 cleavage product. Full-length inhibitory XIAP decreased more and p29 concomitantly increased more during combined treatment with CD/5-FC and TRAIL. In contrast, no cooperative effect was seen in LAN-5 cells treated with 5-FC and TRAIL.
The cleavage of XIAP mirrored the activation of caspase-3. There was no activation by CD/5-FC at 48 h, limited activation by TRAIL and obvious activation by CD/5-FC plus TRAIL as detected by cleavage of the proform and appearance of the cleavage products p20 and p17. Paralleling the activation of caspase-3 its substrate PARP was cleaved, with total cleavage evident only when TRAIL was added to CD/5-FC. Surprisingly, CD-5/FC led to an upregulation of FLIP L mRNA, which was ablated by the addition of TRAIL (Figure 6a ).
Since FLIP L is known to be degraded by the proteasome following ubiquitination, 52 activation of the proteasome may decrease FLIP L . We investigated, whether CD/ 5-FC or TRAIL increased proteasomic function. However, there was no evidence, that CD/5-FC and TRAIL altered global proteasomic capacity (Figure 6b) .
Taken together, these data do not show that FLIP L mediates the cooperation between CD/5-FC and TRAIL in LAN-5 cells.
CD/5-FC and TRAIL cooperate to control growth of LAN-5-CD tumors in mice
Finally, we wanted to know whether CD/5-FC and TRAIL are effective in vivo in established LAN-5 tumors. TRAIL alone injected into the tumors did not decrease their growth (Figure 7) , mirroring the in vitro data. CD/5-FC alone attenuated tumor growth. Attenuation was transient, probably because administration of 5-FC was stopped on day 13. Importantly, TRAIL and CD/5-FC given together eradicated one out of five tumors and caused dramatic tumor regression in the rest. Regression was transient, likely reflecting early cessation of TRAIL and 5-FC administration. Toxicity was not noted during treatment, since weight loss was limited and of the same degree in all groups (data not shown) and because no mice died before being killed. Thus, TRAIL cooperates in vivo with CD/5-FC in the treatment of LAN-5 neuroblastomas without overt toxicity.
Discussion
In this study, we aimed to determine whether CD/5-FC gene therapy and TRAIL cooperate to kill TRAILresistant tumor cells and to define the mechanisms involved. We reasoned that the very high intracellular 5-FU concentrations achievable by CD/5-FC compared to conventional administration of 5-FU would lead to a superior cooperative effect and that the confinement of CD/5-FC to the tumor would preclude a cooperative effect on normal tissues. Indeed, systemic administration of 5-FC in conjunction with intratumoral application of TRAIL dramatically curtailed growth of established s.c. LAN-5-CD tumors resistant to TRAIL, without marked toxicity. Synergism has been reported for agonistic TRAIL antibodies. 53 The present paper delineates the cooperative effects between recombinant soluble TRAIL and CD/5-FC. There are important differences between TRAIL antibodies and soluble TRAIL. Most notable, in contrast to agonistic antibodies, recombinant soluble TRAIL acts on both TRAIL receptors.
Many tumor cells are resistant to TRAIL. Given that most normal tissues are protected against the effects of TRAIL, sensitizing these resistant tumors may be of great clinical relevance. LAN-5 neuroblastoma cells are, like many neuroblastoma cells 27, 54, 55 resistant to TRAIL. We could not implicate methylation of the caspase-8 and 10 genes, which are silenced in many embryonal tumors including neuroblastoma due to methylation 54 or gene deletion, in the resistance of LAN-5 cells to TRAIL, since these genes were expressed at normal levels as determined by Western blotting (Figure 4 ; data not shown). Also, TRAIL-R1 or TRAIL-R2 was not downregulated (data not shown). Furthermore, TRAIL activated caspase-8 and decreased FLIP L , arguing against a role of FLIP L in the resistance of LAN-5 against TRAIL. Thus, other mechanisms of resistance, such as the expression of XIAP or other antiapoptotic molecules or decreased activity of proapoptotic molecules, may cause TRAIL resistance in LAN-5 cells and warrant further study.
Little is known about the mechanisms of CD/5-FCinduced apoptosis. We show that apoptosis of LAN-5 cells mediated by CD/5-FC depends on caspase activation, since caspases became activated, PARP was cleaved and apoptosis was inhibited by the broad-spectrum caspase inhibitor Z-VAD.FMK. Like in glioma cells, 39 CD/5-FC-induced apoptosis in LAN-5 cells was not caused by p53-mediated transactivation of Bax. CD/5-FC did not downregulate Bcl-2 in LAN-5 cells, in contrast to glioma cells, 39 nor did it upregulate the p53 target gene TRAIL-R2. Thus, the mechanisms of CD/5-FC-induced apoptosis remain incompletely understood.
Understanding the mechanisms of cooperation between CD/5-FC and TRAIL is important for the improvement Apo2L/TRAIL and CD/5-FC J Wei et al of this approach and may provide general insight into how to overcome TRAIL resistance. TRAIL is known to induce cell death by caspase activation and we show that caspase activation is also required for CD/5-FC-mediated apoptosis. Since activation of caspases by one stimulus may sensitize to activation by the other stimulus, cooperation between CD/5-FC and TRAIL may ensue from concerted caspase activation. This was indeed the case, since blocking caspase activation by Z-VAD.FMK abrogated cooperation. This led to the question, whether decreases of antiapoptotic proteins may be associated with the observed increase of caspase activation and of apoptosis. While downregulation of Bcl-2 and Bcl-XL 39 and of c-Flip 36 has been described to contribute to sensitization between 5-FU and TRAIL, this is the first report to implicate decreased XIAP levels in the cooperation between 5-FU-based approaches and TRAIL-receptor activating moieties in general, and between CD/5-FC and recombinant soluble TRAIL in particular. Since both death receptor-mediated and mitochondrial-mediated or -amplified apoptotic pathways converge upon the downstream effector caspases 3, 7 and 9, which are inhibited by XIAP, decreasing functional XIAP will strongly sensitize to either pathway. TRAIL-induced apoptosis is known to be inhibited by XIAP 56, 57 and we have shown, that CD/5-FC-induced apoptosis depends on activation of caspases including those inhibited by XIAP. Thus, the decrease of XIAP observed during CD/5-FC with TRAIL should sensitize strongly to both treatment modalities.
Although TRAIL did not trigger significant apoptosis in LAN-5 cells, it did induce low-level activation of caspase-3 as determined by cleavage of caspase-3 and its substrate PARP. Concomitantly, there was limited inactivation of XIAP. This partial inactivation of XIAP may have been sufficient to increase caspase signaling by the 5-FU that had accumulated intracellulary over 48 h, since CD/5-FC-induced apoptosis is caspase dependent. As part of accelerating apoptotic signaling during cooperation, caspase-3 activation was increased causing enhanced inactivation of XIAP. This may have further facilitated caspase activation both by the accumulated 5-FU and the bound TRAIL leading to a positive amplification loop. Taken together, our data are consistent with a role of caspase-3-mediated XIAP inactivation in the cooperation between TRAIL and CD/5-FC.
TRAIL has been shown to release Smac/DIABLO from mitochondria of neuroblastoma cells overexpressing N-myc, associated with decreased levels of XIAP. 57 Smac/ DIABLO inhibits XIAP by binding to its BIR 1 and 2 domains leading to loss of inhibition of caspase-3 and caspase-9, respectively. 58, 59 This will lead to increased caspase-3 activity that cleaves XIAP. Taken together, both inhibition and cleavage of XIAP by TRAIL-induced release of Smac/DIABLO may have contributed to the cooperative effect between TRAIL and CD/5-FC.
Inactivation of XIAP following CD/5-FC was not mediated by increased proteasomic degradation since inactivation of XIAP was clearly by cleavage, not by degradation of full-length XIAP.
We found no evidence in LAN-5 cells that CD/5-FC acting for 48 h decreases protein or mRNA levels of FLIP L . Surprisingly and for reasons yet unknown, FLIP L transcription increased following CD/5-FC but normalized again after addition of TRAIL. TRAIL alone caused ablation of FLIP L protein, possibly by activated caspase-8 and caspase-3, 60, 61 precluding an analysis of cooperation between CD/5-FC and TRAIL on FLIP L protein levels. That we did not detect cleavage products of FLIP L may reflect quick processing of the cleavage products. CD/5-FC and TRAIL did not increase the overall activity of the proteasome. This supports the notion that ablation of FLIP L by CD/5-FC was not caused by proteasomic degradation, although by itself does not rule out increased proteasomic degradation specific for FLIP L , as occurs in p53-induced proteasomic FLIP L degradation in colon cancer cells. 52 While we could not demonstrate a role of Bax, Bcl-2, survivin or Id2 in the cooperative effect on apoptosis between CD/5-FC and TRAIL (Figure 4 ; data not shown), the possible involvement of other pro-and antiapoptotic molecules warrants further investigation.
Nonapoptotic mechanisms may contribute to the cooperative effect between CD/5-FC and TRAIL. CD/ 5-FC induced p53 that upregulated p21. This may have caused the proliferation arrest that preceded the onset of CD/5-FC-induced apoptosis (data not shown). CD/5-FCinduced arrest of proliferation in LAN-5 cells was not associated with senescence, as neither p16 nor senescenceassociated b-galactosidase was upregulated.
The efficacy of CD/5-FC with TRAIL may be enhanced by employing more effective CD constructs, such as fusion genes of CD and uracil phosphoribosyl transferase. 62 As tumor growth resumed after TRAIL was given for only a short period, prolonging TRAIL administration may be required. Furthermore, taking advantage of the immune response in an immune competent host may increase the final elimination of CD-bearing tumor cells.
Several challenges have to be met before application of this approach in the patient can be considered. First, as with all suicide gene therapies, efficient in situ gene transfer has to be assured. Gene transfer into a fraction of the tumor cells will suffice, since LAN-5-CD plus 5-FC exerted a bystander effect on nontransduced LAN-5 cells and because this bystander effect was augmented by TRAIL (data not shown). Second, while intratumoral injection is an appropriate route for accessible and localized tumors, targeting inaccessible or metastatic tumors will require systemic administration of TRAIL. Third, appropriate tumors have to be chosen, since a lack of expression of crucial caspases such as caspase-8, as found in some neuroblastomas and other embryonal tumors, will attenuate the cooperative effect between CD/ 5-FC and TRAIL, which depends on caspases. If these challenges are met, CD/5-FC with TRAIL may have potential in patients with TRAIL-resistant tumors.
